The International Myasthenia Gravis/COVID-19 Working Group has published a short guidance statement on the management of MG and Lambert-Eaton myasthenic syndrome during this novel pandemic.
Zilucoplan yielded rapid, clinically meaningful, and sustained improvement in patients with moderate to severe generalized myasthenia gravis.
The Food and Drug Administration has granted Orphan Drug designation to zilucoplan for the treatment of generalized myasthenia gravis and other rare, tissue-based complement-mediated diseases.
Alexion announced the publication of data from the phase 3 open-label extension of the REGAIN trial (ECU-MG-302) that assessed the long-term safety and efficacy of eculizumab (Soliris) for the treatment of adults with anti-acetylcholine receptor (AChR) antibody-positive refractory generalized myasthenia gravis (gMG).
For patients with non-thymomatous myasthenia gravis, thymectomy plus prednisone confers benefits versus prednisone alone at 5 years.
The investigators suggest that the recruited participants may have reached a plateau in symptoms, which may have decreased the chances of additional improvement with belimumab treatment.
Results from the Phase 3 trial showed that the Quantitative Myasthenia Gravis (QMG) score at baseline to day 14 changed from 6.4 to 6.7 in the amifampridine group vs. 5.6 to 7.9 for the placebo group.
The Myasthenia Gravis Impairment Index was developed to incorporate patient input at different stages of disease progression.
Treatment with eculizumab was associated with a significant benefit on quality of life.
The FDA has approved Soliris for treating adults with myasthenia gravis.
